Indinavir

Generic Name: Indinavir

Brand Names: Crixivan

Drug Type: Small Molecule

Chemical Formula: C_₃₆H_₄₇N_₅O_₄

CAS Number: 150378-17-9

Unique Ingredient Identifier: 9MG78X43ZT

Background: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]

Indication: Indinavir is an antiretroviral drug for the treatment of HIV infection.

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir

Phase 2

Completed

Conditions: Classical Kaposi's Sarcoma

First Posted Date: 2006-08-10

Last Posted Date: 2008-04-14

Lead Sponsor: Istituto Superiore di Sanità

Target Recruit Count: 28

Registration Number: NCT00362310

Locations: 🇮🇹
Department of Dermatological/Venereal Diseases and Plastic Surgery, University "La Sapienza", Rome, Italy
🇮🇹
Dermatology Clinic, University of Sassari, Sassari, Italy
🇮🇹
Istituto Dermatologico S. Gallicano-IRCCS, Rome, Italy

and more 6 locations

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Phase 4

Completed

Conditions: HIV-Associated Lipodystrophy Syndrome
Cardiovascular Disease

First Posted Date: 2005-09-19

Last Posted Date: 2012-04-12

Lead Sponsor: Kirby Institute

Target Recruit Count: 80

Registration Number: NCT00192660

Locations: 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia

Evaluation of Therapeutic Drug Monitoring of Protease Inhibitors on Virologic Success and Tolerance of Highly Active Antiretroviral Therapy (HAART)

Not Applicable

Terminated

Conditions: HIV Infections

First Posted Date: 2005-07-22

Last Posted Date: 2005-08-01

Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Target Recruit Count: 115

Registration Number: NCT00122590

Locations: 🇫🇷
Service de Medecine Interne Hopital Cochin, Paris, France

Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance

Phase 2

Terminated

Conditions: HIV Infections

First Posted Date: 2005-07-19

Last Posted Date: 2007-01-18

Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Target Recruit Count: 40

Registration Number: NCT00120783

Locations: 🇫🇷
Service de Medecine Interne hopital Avicenne, Bobigny, France

A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection

Phase 1

Completed

Conditions: Acquired Immunodeficiency Syndrome
HIV Infections

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 63

Registration Number: NCT00001443

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers

Phase 4

Completed

Conditions: Healthy
HIV Infections

First Posted Date: 2002-11-26

Last Posted Date: 2017-07-02

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 81

Registration Number: NCT00050180

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers

Phase 1

Completed

Conditions: Cardiovascular Diseases
HIV Infections
Hypertension

First Posted Date: 2002-06-20

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 32

Registration Number: NCT00039975

Locations: 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸
Cornell Univ Med Ctr, New York, New York, United States
🇺🇸
Univ of California San Francisco, San Francisco, California, United States

and more 6 locations

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-12-05

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 53

Registration Number: NCT00027339

Locations: 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇺🇸
Beth Israel Med. Ctr., ACTU, New York, New York, United States

and more 11 locations

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2014-04-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1710

Registration Number: NCT00000922

Locations: 🇺🇸
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States
🇺🇸
Washington Reg AIDS Prog / Dept of Infect Dis, Washington, District of Columbia, United States
🇺🇸
Harlem AIDS Treatment Grp / Harlem Hosp Ctr, New York, New York, United States

and more 14 locations

The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 144

Registration Number: NCT00000848

Locations: 🇺🇸
Stanford CRS, Palo Alto, California, United States
🇺🇸
Ucsf Aids Crs, San Francisco, California, United States
🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States

and more 13 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy